CLAIMS

1. Use of ~~A~~a prophylactic and/or therapeutic agent ~~for diabetes,~~ comprising mesenchymal stem cells in the manufacture of a medicament for treating diabetes, wherein the diabetes is caused by an immune checkpoint inhibitor.

~~2. The prophylactic and/or therapeutic agent for diabetes according to claim 1, wherein the diabetes is diabetes caused by an immune checkpoint inhibitor.~~

2~~3~~. The ~~prophylactic and/or therapeutic agent for diabetes~~use according to claim 1 ~~or 2~~, wherein the diabetes is diabetes caused by an anti-PD-1 antibody or an anti-PD-L1 antibody.

3~~4~~. The ~~prophylactic and/or therapeutic agent for diabetes~~use according to ~~any of~~ claim~~s~~ 1 or~~to~~ 2~~3~~, wherein the mesenchymal stem cells are allogeneic to a subject.

4~~5~~. The ~~prophylactic and/or therapeutic agent for diabetes~~use according to any of claims 1 to 3~~4~~, wherein the mesenchymal stem cells are derived from fat~~adipose~~, umbilical cord, or bone marrow.

6~~5~~. ~~A kit for preventing and/or treating diabetes, comprising the prophylactic and/or therapeutic agent for diabetes according to any of claims 1 to 5~~The use according to any of claims 1 to 4, wherein the medicament is comprised in a container carrying~~,~~ ~~and~~ a label.